Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction
Authors:
- Michael EdlingerMEMichael Edlinger
- F. WeidingerFWF. Weidinger
- for the Austrian Acute PCI InvestigatorsFIfor the Austrian Acute PCI Investigators
- M. PichlerMPM. Pichler
- G. BonnerGBG. Bonner
- T. BrunnerTBT. Brunner
- G. GaulGGG. Gaul
- F. GratzeFGF. Gratze
- M. JuhaszMJM. Juhasz
Open Access
- 14 September 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 32 (23) , 2954-2961
Abstract
Pre-treatment with clopidogrel results in a reduction of ischaemic events in non-ST-elevation acute coronary syndromes. Data on upstream clopidogrel in the setting of primary percutaneous coronary intervention (PCI) are limited. The aim of this study was to investigate whether clopidogrel loading before arrival at the PCI centre may result in an improved outcome of primary PCI for ST-elevation myocardial infarction (STEMI). In a multicentre registry of acute PCI, 5955 patients undergoing primary PCI in Austria between January 2005 and December 2009 were prospectively enrolled. The patients consisted of two groups, a clopidogrel pre-treatment group (n = 1635 patients) receiving clopidogrel before arrival at the PCI centre and a peri-interventional clopidogrel group (n = 4320 patients) receiving clopidogrel at a later stage. Multiple logistic regression analysis including major confounding factors stratified by the participating centres was applied to investigate the effect of pre-treatment with clopidogrel on the in-hospital mortality. Additionally, two subgroups, with or without the use of GP IIb/IIIa antagonist therapy in the catheterization laboratory, were analysed. On univariate analysis, clopidogrel pre-treatment was associated with a reduced in-hospital mortality (3.4 vs. 6.1%, P< 0.01) after primary PCI. On multivariate analysis, clopidogrel pre-treatment remained an independent predictor of in-hospital mortality [odds ratio (OR) = 0.60, 95% confidence interval (CI) 0.35–0.99; P =0.048], especially in patients receiving additional GP IIb/IIIa antagonist therapy in the catheterization laboratory (OR = 0.40, 95% CI 0.19–0.83; P =0.01). Clopidogrel pre-treatment before arrival at the PCI centre is associated with reduced mortality in a real world setting of primary PCI. These results strongly support the recommendation of clopidogrel treatment ‘as soon as possible’ in patients with STEMI undergoing pimary PCI.Keywords
This publication has 28 references indexed in Scilit:
- The 2010 ESC/EACTS guidelines on myocardial revascularisationHeart, 2010
- Pharmacologic Therapy for Non ST-segment Elevation Acute Coronary Syndromes: Focus on Antithrombotic TherapyCardiovascular Drugs and Therapy, 2010
- Primary percutaneous intervention of ST-elevation myocardial infarction in Austria: Results from the Austrian acute PCI registry 2005–2007Wiener klinische Wochenschrift, 2010
- Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countriesEuropean Heart Journal, 2009
- Management of acute myocardial infarction in patients presenting with persistent ST-segment elevationEuropean Heart Journal, 2008
- 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial InfarctionJACC, 2008
- Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trialThe Lancet, 2005
- Design and rationale of Clopidogrel as Adjunctive Reperfusion Therapy–Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 trialAmerican Heart Journal, 2005
- The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practiceEuropean Heart Journal, 2004
- Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trialsThe Lancet, 2003